Oncogene News and Research RSS Feed - Oncogene News and Research

An oncogene is a gene that, when mutated or expressed at high levels, helps turn a normal cell into a tumor cell.
AACR to honor Lewis C. Cantley with Princess Takamatsu Memorial Lectureship

AACR to honor Lewis C. Cantley with Princess Takamatsu Memorial Lectureship

The American Association for Cancer Research will honor Lewis C. Cantley, PhD, with the ninth annual Princess Takamatsu Memorial Lectureship at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22. [More]
Shp2 enzyme blocks protection program, boosts tumor growth

Shp2 enzyme blocks protection program, boosts tumor growth

Cells have two different programs to safeguard them from getting out of control and developing cancer. One of them is senescence (biological aging). It puts cancer cells into a permanent sleep so they no longer divide and grow in an uncontrolled way. [More]
Penn researchers find evidence of new culprit in colon cancer

Penn researchers find evidence of new culprit in colon cancer

Colon cancer is a heavily studied disease -- and for good reason. It is one of the leading causes of cancer-related deaths worldwide, and its numbers are on the rise, from 500,00 deaths in 1990 to 700,000 in 2010. [More]
Study supports use of ThyraMIR, ThyGenX Thyroid Oncogene Panel to improve thyroid cancer diagnosis

Study supports use of ThyraMIR, ThyGenX Thyroid Oncogene Panel to improve thyroid cancer diagnosis

PDI, Inc. subsidiary, Interpace Diagnostics, announced today new data supporting the use of combination platform testing with ThyraMIR, the first and only microRNA expression classifier, and ThyGenX Thyroid Oncogene Panel, a DNA and RNA mutational analysis, to improve thyroid cancer diagnosis. [More]
Pediatric Cancer Genome Project identifies genetic basis of three pediatric melanoma subtypes

Pediatric Cancer Genome Project identifies genetic basis of three pediatric melanoma subtypes

The St. Jude Children's Research Hospital—Washington University Pediatric Cancer Genome Project found that melanoma in some adolescent and adult patients involves many of the same genetic alterations and would likely respond to the same therapy. [More]
Novogen's TRXE-009 therapy shows promise against brain cancer

Novogen's TRXE-009 therapy shows promise against brain cancer

Australian/US biotechnology company, Novogen Limited, today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer. [More]
New study finds increase in use of adjuvant systemic therapy for gastrointestinal stromal tumors

New study finds increase in use of adjuvant systemic therapy for gastrointestinal stromal tumors

A new study finds that the use of adjuvant systemic therapy for localized gastrointestinal stromal tumors (GISTs ) has significantly increased over time and that patients treated with the therapy have better survival than those treated with surgery alone. [More]
Common protein may play strategic role in tumor growth

Common protein may play strategic role in tumor growth

A common, yet previously undistinguished protein, which is elevated in many late-stage cancers, may play a strategic role in tumor growth through a non-conventional pathway, researchers at the Indiana University School of Medicine report in the Feb. 10 issue of the Proceedings of the National Academy of Sciences. [More]
Trovagene to sell underwritten public offering of common stock

Trovagene to sell underwritten public offering of common stock

Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced that it is offering to sell shares of its common stock in an underwritten public offering. The offering is expected to price on or about Friday, February 6, 2015. [More]
Genomics of papillary thyroid carcinoma (PTC): an interview with Professor Thomas J. Giordano

Genomics of papillary thyroid carcinoma (PTC): an interview with Professor Thomas J. Giordano

There are two types of thyroid cells and therefore there are two broad types of thyroid cancer. Medullary carcinoma is derived from parafollicular or C cells, whereas follicular cells give rise to several types of thyroid cancers. [More]
Study provides common model of cellular ageing

Study provides common model of cellular ageing

Researchers at the BBSRC-supported Babraham Institute have mapped the physical structure of the nuclear landscape in unprecedented detail to understand changes in genomic interactions occurring in cell senescence and ageing. Their findings have allowed them to reconcile the contradictory observations of two current models of ageing: cellular senescence of connective tissue cells called fibroblasts and cellular models of an accelerated ageing syndrome. [More]
Damon Runyon Cancer Research Foundation names 15 new Damon Runyon Fellows

Damon Runyon Cancer Research Foundation names 15 new Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 15 new Damon Runyon Fellows at its fall Fellowship Award Committee review. The recipients of this prestigious, four-year award are outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators across the country. [More]
Androgen receptor in prostate cancer cells can activate different gene set when bound to antiandrogens

Androgen receptor in prostate cancer cells can activate different gene set when bound to antiandrogens

The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. [More]
NMR in cancer research: an interview with Andy Byrd

NMR in cancer research: an interview with Andy Byrd

My research these days is generally classified as structural biology, although as I trained in chemistry. I specialize in nuclear magnetic resonance (NMR) applied to biological problems. Our lab is very interested in studying mammalian proteins, particularly systems involved in cancer, in order to try to understand mechanisms to provide that information for our collaborators, and for the general knowledge of the community as well. [More]
Trovagene, Genomac Research Institute to expand clinical collaboration

Trovagene, Genomac Research Institute to expand clinical collaboration

Trovagene, Inc., today announced it will expand the clinical collaboration with Genomac Research Institute in Prague, Czech Republic. Trovagene Precision Cancer Monitoring SM technology will be used in two prospective clinical studies for the early detection of emerging oncogene mutations indicative of resistance to targeted therapies used to treat colorectal and lung cancer. [More]
MET amplified in NSCLC irrespective of type, genetic background

MET amplified in NSCLC irrespective of type, genetic background

A third of non-small-cell lung cancers show low- to high-level amplification of the MET gene, according to a German study, with no significant difference in frequency across different types of cancer and genetic backgrounds. [More]
CML mouse model reveals previously unreported facets of disease

CML mouse model reveals previously unreported facets of disease

A humanised murine model of chronic phase chronic myeloid leukaemia, developed by a Swedish research team, provides insight into previously unexplored characteristics of the disease. [More]
PF-114 shows promise in therapy-resistant CML, Ph-positive ALL

PF-114 shows promise in therapy-resistant CML, Ph-positive ALL

PF-114, a selective tyrosine kinase inhibitor, is active against native and mutated forms of the BCR–ABL oncogene in Philadelphia chromosome-positive leukaemias, according to preclinical cellular and in vivo results published in Leukemia. [More]
Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma. [More]
Metastatic lung cancer outcomes independent of KRAS mutation subtypes

Metastatic lung cancer outcomes independent of KRAS mutation subtypes

Overall survival in patients with metastatic lung cancer does not correlate with Kirsten rat sarcoma viral oncogene homologue mutation subtypes, US researchers report. [More]
Advertisement
Advertisement